The purpose of this study is to find out if two new treatment cancer vaccines called SCIB1 and iSCIB1+ can be used safely when added to nivolumab (Opdivo) with ipilimumab (Yervoy), or SCIB1 with pembrolizumab (Keytruda). Pembrolizumab or nivolumab with ipilimumab are standard treatments already approved in the UK for the treatment of advanced melanoma (skin cancer). These standard treatments are antibody treatments for cancer. The study will also look to see if SCIB1 or iSCIB1+ can increase the likelihood that ...

GO TO STUDY

SIOP-HRMB is an international phase III clinical trial in children, young people and adults with high risk medulloblastoma (HR-MB). The prognosis for patients with HR-MB is poor, with only 60% of patients cured. Those that are cured suffer significant long-term side effects mainly associated with radiotherapy, which can severely affect the quality of life for these patients. This trial aims to improve survival for this group of patients, while limiting the impact of side effects. The trial consists of two randomised ...

GO TO STUDY

Hydroxychloroquine (HCQ) is widely used for joint and skin disorders. It is also being investigated for the possible prevention and/or treatment of COVID19 [1]. However in some patients long-term HCQ use, for joint and skin disorders, can lead to the retina (part of the eye) becoming damaged (HCQ retinopathy), leading to irreversible blindness. In the UK, regular retinal screening is recommended for those taking HCQ, costing the NHS millions per year. Unfortunately, this only identifies the problem after it has ...

GO TO STUDY

Polycythemia vera (PV) is a rare blood cancer characterised by a high-risk of thrombosis (clotting) and haemorrhage (bleeding). Average survival in high-risk patients receiving contemporary care is 10.9 years. Current treatments include aspirin, venesection (blood drawing) and selected use of standard therapies (hydroxycarbamide (HC) or interferon alpha (IFNa)). The strategies remain less than perfect, with on-going risks of developing blood clots, bleeding, dying early due to either these events or to the disease progressing into leukaemia or a more aggressive ...

GO TO STUDY

Anonymised copies of normal and abnormal digital mammograms are collected from clinical sites. Real and simulated images of lesions are used to measure the ability of radiologists to detect breast cancer when various technical factors are adjusted.

GO TO STUDY

This is a first-in-human, randomised (treatment is assigned by chance), study to evaluate the safety, tolerability and the pharmacokinetics [how a drug is processed] (PK) of multiple doses of the study drug (BIIB101) in adults with Multiple System Atrophy (MSA). Participants will receive either the study drug or a placebo (medication made of an inactive material). The study drug has been tested in animals but, since the study drug has not yet been tested in humans, the safety in ...

GO TO STUDY

Aim: To establish laboratory tests for measuring the composition of human breast milk Outline of research: This study involves the collection of 1-2 teaspoons of breast milk (up to 10 mls) from up to 30 women who are already expressing milk for their babies in the Oxford Newborn Care Unit, Women’s Centre, John Radcliffe Hospital, Oxford The women are healthy volunteers and are recruited by virtue that their babies are NHS patients. Duration of participant involvement will be around 45 min. ...

GO TO STUDY

CCS1477 is a new experimental medication (sponsored by CellCentric Ltd) for a group of cancers that effect the blood and/or bone marrow. These include Acute Myeloid Leukaemia (AML), high-risk Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Non-Hodgkin Lymphoma (NHL). It is aimed at tumours that are not responsive to, or have become resistant to, existing medications used in late stage disease. The purpose of this study is to examine the safety, tolerability, pharmacokinetics (PK) and efficacy of CCS1477 when treating patients ...

GO TO STUDY

PURA Syndrome was first described in 2014 in a small cohort of children, and since then just over 250 individuals have been identified to have the condition internationally. PURA syndrome typically causes severe developmental delay and intellectual disability. Many also suffer with hypotonia (severe floppiness), feeding difficulties and breathing abnormalities in infancy, and many develop seizures in early childhood. We are designing a longitudinal natural history study, with the aim to collect medical data on individuals with PURA Syndrome. We ...

GO TO STUDY

Hepatocellular carcinoma (HCC) and cholangiocarcinoma are the two most common causes of primary liver cancer and HCC is the second highest cause of cancer death worldwide. It is known that most of these cancers occur in patients who already have a liver condition. Despite close monitoring of many patients who have liver disease with regular ultrasound scans, HCC and cholangiocarcinoma are often discovered at a late stage. This is because they rarely cause symptoms until they have ...

GO TO STUDY